We understand the power of expertise, so we gathered leading scientists in the field of longevity to drive our in-house research. We also created a select network of research institutions to focus on some of mankind’s biggest biological questions with us.

Our scientific partnerships not only allow us to contribute to the advancement of cellular longevity research, but also result in safe, lab-tested products grounded in scientific rigor.

scientific Advisory Board

Seneque’s Scientific Advisory Board guides research and development across our organization.
The Scientific Advisory Board is led by Dr. Eric Verdin, a recognized NAD+ expert and President
of the Buck Institute for Research on Aging, and supported by Chief Scientist Dr. Alessia Grozio.



Dr. Verdin is the President of the Buck Institute for Research on Aging, a Professor of Medicine at the University of California, and the Chair of Seneque’s Scientific Advisory Board.


Dr. Verdin studies the relationship between aging and the immune system. His lab at the Buck Institute has demonstrated how changes in the relative abundance of key cellular metabolites such as NAD+ influence immune responses and the age-related state of chronic inflammation.

Dr. Verdin has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging, and a senior scholarship from the Ellison Medical Foundation.

He is an elected member of the American Association for the Advancement of Science,
the American Society for Clinical Investigation, and the Association of American Physicians.

Alejandro Ocampo

Assistant Professor Department of Biomedical Science University of Lausanne

Dr. Ocampo is an Assistant Professor at the University of Lausanne in Switzerland. Hislaboratory is focused on understanding the role of epigenetic dysregulation as driver of aging and the development of therapies to prevent the manifestation of age-associated diseases.


Dr. Ocampo obtained his PhD in 2012 from the University of Miami. Between 2013 and 2017, he carried out a postdoc with Juan Carlos Belmonte at the Salk Institute where he developed a novel technology to prevent the transmission of mitochondrial diseases. In addition, during his postdoc he performed pioneer work to demonstrate the amelioration of age-associated hallmarks by partial cellular reprogramming opening up a new field of research. In August 2018, he joined the University of Lausanne in Switzerland.



Dr. Grozio is Seneque’s Chief Scientist
and researcher at the Buck Institute for Research on Aging.


As part of a team at Washington University School of Medicine, Dr. Grozio identified a previously unknown pathway used by NMN to restore NAD+ levels.

Thanks to this groundbreaking identification and characterization of a novel NMN transporter, Dr. Grozio significantly advanced understanding of NAD+ absorption and opened the door to more effective methods of NMN delivery.

Dr. Grozio earned her PhD in biochemistry at the University of Genoa in Italy and has been recognized for her research with a Tanaka Scholarship and Edward Schulak Scholarship.
As a recognized leader in the field of NAD+ metabolism and aging, she is a regular speaker at research conferences, seminars, and workshops around the world.


One of our primary research partners is the Buck Institute for Research of Aging, a collective of the world’s top scientists in the field of aging, located in Novato, California.
We collaborate on a range of research programs to deepen our understanding of the efficacy of NMN on longevity.
In partnership with the Buck Institute, we are helping turn fundamental biological discoveries into realities.